Sees Q3 organic revenue growth low double digits, consensus $9.79B. Sees Q3 COVID-19 testing-related sales about $100M. Guidance taken from Q2 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott reports Q2 worldwide Medical Devices sales up 13.5% on reported basis
- Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
- Abbott sees FY23 organic sales growth in low double digits, consensus $39.65B
- Abbott FY23 adjusted EPS view $4.30-$4.50, consensus $4.40